新辅助化疗对胃癌患者预后和术后转移的影响

Effect of neoadjuvant chemotherapy on prognosis and postoperative metastasis in patients with gastric cancer

目的:探讨新辅助化疗对胃癌患者预后和术后转移的影响。方法:将2008年1月至2010年1月期间于我院确诊为胃癌的患者100例按治疗方法分为观察组和对照组,每组患者50例。对照组采取常规治疗且均未接受新辅助化疗,观察组在对照组的基础上进行至少2周的新辅助化疗,治疗后患者均随访5年。比较两组的疗效、预后和术后转移情况。结果:观察组治疗有效率为76%,高于对照组的58%(P<0.05)。观察组术后发生肝转移、骨转移、淋巴结转移等术后转移发生率较对照组降低,观察组无瘤生存期和总生存期则均较对照组延长(P<0.05)。结论:新辅助化疗治疗胃癌疗效良好,可有效改善患者的预后并减少术后转移的发生,值得临床推广使用。

Objective： To explore the effect of neoadjuvant chemotherapy （NAC） on prognosis and postoperative metastasis in patients with gastric cancer. Methods： One hundred gastric cancer patients diagnosed and treated in our hospital from January, 2009 to January, 2010 were divided into an observation group and a control group with 50 cases each according to the method for treatment. The control group was treated with conventional treatment without neoadjuvant chemotherapy while the observation group was treated with neoadjuvant chemotherapy for at least two weeks in the basis of the control group. Patients were followed up for 5 years after treatment. The efficacy, prognosis, and postoperative metastasis in two groups were compared. Results： The treatment efficiency was 76% in the observation group, which is higher than the 58% in the control group （P〈0.05）. The incidence of liver metastases, bone metastases, lymph node metastasis and other postoperative metastasis was lower in the observation group than in the control group. The tumor-free survival period and overall survival period were longer in the observation group than in the control group （P〈0.05）. Conclusion： Neoadjuvant chemotherapy for the treatment of gastric cancer has good efficacy and can effectively improve the prognosis of patients and reduce the occurrence of postoperative metastasis, which is worthy of clinical use.